# Phase II Study With ITF2984 in Acromegalic Patients

> **NCT02111044** · PHASE2 · COMPLETED · sponsor: **Italfarmaco** · enrollment: 48 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** Octreotide
- **DRUG:** ITF2984 500 mcg
- **DRUG:** ITF2984 1000 mcg
- **DRUG:** ITF2984 2000 mcg

## Key facts

- **NCT ID:** NCT02111044
- **Lead sponsor:** Italfarmaco
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2016-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02111044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02111044, "Phase II Study With ITF2984 in Acromegalic Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02111044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*